Litcius/Paper detail

The Fourth International Workshop on Clinical Transplant Tolerance

Fadi Issa, Samuel Strober, Joseph R. Leventhal, Tatsuo Kawai, Dixon B. Kaufman, Josh Levitsky, Megan Sykes, Valeria R. Mas, Kathryn J. Wood, Nancy D. Bridges, Lisbeth A. Welniak, Sindhu Chandran, Joren C. Madsen, Peter Nickerson, Anthony J. Demetris, Fadi G. Lakkis, Angus W. Thomson

2020American Journal of Transplantation38 citationsDOIOpen Access PDF

Abstract

The International Workshop on Clinical Transplant Tolerance is a biennial meeting that aims to provide an update on the progress of studies of immunosuppression minimization or withdrawal in solid organ transplantation. The Fourth International Workshop on Clinical Tolerance was held in Pittsburgh, Pennsylvania, September 5-6, 2019. This report is a summary of presentations on the status of clinical trials designed to minimize or withdraw immunosuppressive drugs in kidney, liver, and lung transplantation without subsequent evidence of rejection. All protocols had in common the use of donor or recipient cell therapy combined with organ transplantation. The workshop also included presentations of mechanistic studies designed to improve understanding of the cellular and molecular basis of tolerance and to identify potential predictors/biomarkers of tolerance. Strategies to enhance the safety of hematopoietic cell transplantation and to improve patient selection/risk stratification for clinical trials were also discussed. The International Workshop on Clinical Transplant Tolerance is a biennial meeting that aims to provide an update on the progress of studies of immunosuppression minimization or withdrawal in solid organ transplantation. The Fourth International Workshop on Clinical Tolerance was held in Pittsburgh, Pennsylvania, September 5-6, 2019. This report is a summary of presentations on the status of clinical trials designed to minimize or withdraw immunosuppressive drugs in kidney, liver, and lung transplantation without subsequent evidence of rejection. All protocols had in common the use of donor or recipient cell therapy combined with organ transplantation. The workshop also included presentations of mechanistic studies designed to improve understanding of the cellular and molecular basis of tolerance and to identify potential predictors/biomarkers of tolerance. Strategies to enhance the safety of hematopoietic cell transplantation and to improve patient selection/risk stratification for clinical trials were also discussed.

Topics & Concepts

MedicineImmunosuppressionClinical trialIntensive care medicineTransplantationOrgan transplantationConsensus conferenceImmunologyInternal medicineRenal Transplantation Outcomes and TreatmentsOrgan Transplantation Techniques and OutcomesHematopoietic Stem Cell Transplantation